Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Neurotrope Inc    NTRP

NEUROTROPE INC

(NTRP)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/15/2019 07/16/2019 07/17/2019 07/18/2019 07/19/2019 Date
6.57(c) 6.44(c) 6.2(c) 5.51(c) 5.95(c) Last
94 552 110 352 73 031 164 746 97 186 Volume
+0.46% -1.98% -3.73% -11.13% +7.99% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -20,5 M
Net income 2019 -20,1 M
Debt 2019 -
Yield 2019 -
Sales 2020 -
EBIT 2020 -24,1 M
Net income 2020 -24,1 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -3,81x
P/E ratio 2020 -4,25x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 77,0 M
More Financials
Company
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's... 
Sector
Software
Calendar
-
More about the company
Latest news on NEUROTROPE INC
07/12NEUROTROPE : to Present at the Alzheimer's Association International Conference
AQ
05/09NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Res..
AQ
04/01NEUROTROPE, INC. : Change in Directors or Principal Officers, Financial Statemen..
AQ
03/22NEUROTROPE : NTRP) `Saddened` That Biogen`s Discontinued Phase 3 Trial In Alzhei..
AQ
03/15NEUROTROPE : Completes Enrollment Of Confirmatory Phase 2 Study of Bryostatin-1 ..
AQ
03/08NEUROTROPE : Management's Discussion and Analysis of Financial Condition and Res..
AQ
02/06NEUROTROPE : Announces Cooperative Research and Development Agreement for Bryost..
AQ
2018NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale..
AQ
2018NEUROTROPE : Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate ..
AQ
2018NEUROTROPE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale..
AQ
More news
Sector news : Software - NEC
05:45aTech Rally Powers Record Gains for Stocks
DJ
07/19WHITE HOUSE TO HOST MEETING WITH TEC : sources
RE
07/19Four Republican lawmakers ask Trump to move forward with $10 billion Pentagon..
RE
07/19Microsoft Showing DJIA's Second-Largest Gains Friday
DJ
07/19GLOBAL MARKETS LIVE : T-Mobile, Sprint, Boeing, AB InBev…
More sector news : Software - NEC
Chart NEUROTROPE INC
Duration : Period :
Neurotrope Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROTROPE INC
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 14,00  $
Last Close Price 5,95  $
Spread / Highest target 135%
Spread / Average Target 135%
Spread / Lowest Target 135%
EPS Revisions
Managers
NameTitle
Charles S. Ryan Chief Executive Officer & Director
Daniel Alkon President & Chief Scientific Officer
Joshua Nathaniel Silverman Chairman
Robert Weinstein CFO, Secretary, Treasurer & Executive VP
William S. Singer Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
NEUROTROPE INC66.67%77
MICROSOFT CORPORATION34.31%1 044 187
ATLASSIAN CORPORATION PLC50.78%32 341
SPLUNK INC31.75%20 745
CADENCE DESIGN SYSTEMS INC.71.85%20 493
SYNOPSYS61.49%20 235